Loading organizations...
Modern Meadow is a biotechnology company focused on developing advanced biofabricated materials. The company’s flagship product, INNOVERA, is a next-generation leather alternative crafted from plant proteins and recycled rubber. This material is engineered to replicate the aesthetic and performance characteristics of traditional leather, providing a versatile and sustainable solution for various applications.
The company was founded by Andras Forgacs, launching in 2011 with an ambitious vision for bio-design. Forgacs, a serial entrepreneur in deep tech and life sciences, identified an opportunity to create fundamentally new materials with superior properties through biofabrication. His initial insight extended to both meat and leather, pioneering a novel approach to material science.
Modern Meadow targets industries that demand high-performance, sustainable inputs, with a notable presence in luxury fashion. The company's long-term vision centers on redefining the possibilities of materials through innovative bio-design, offering animal-free alternatives that aim to surpass conventional options in terms of sustainability, performance, and scalability.
Modern Meadow has raised $184.0M across 4 funding rounds.
Modern Meadow has raised $184.0M in total across 4 funding rounds.
Modern Meadow has raised $184.0M across 4 funding rounds. Most recently, it raised $130.0M Series C in April 2021.
Modern Meadow has raised $184.0M in total across 4 funding rounds.
Modern Meadow's investors include Key Partners Capital, Astanor Ventures, B Capital Group, Jacob Conger, iNovia Capital, Panache Ventures, Preface Ventures, Stellar Capital, Talis Capital, Tribe Capital, Bart Swanson, Moshe Lifschitz.
Modern Meadow is a sustainable bio-design technology company that develops animal-free, biofabricated leather alternatives and protein-based materials using synthetic biology and nature-inspired proteins.[2][3] It builds Bio-Alloy™, Bio-F@rm™, and Bio-Coll@gen™ technology platforms, which create high-performance biomaterials like collagen for industries including fashion, footwear, automotive, textiles, personal care, and biomedical.[2][4][5] These solutions serve visionary brands and manufacturers seeking sustainable alternatives to petrochemical and animal-derived inputs, solving problems of environmental impact—such as 95% less water use, 75-80% less energy and chemicals—while delivering superior durability, breathability, abrasion resistance, and scalability through "drop-in" compatibility with existing global manufacturing.[3][5][6] The company demonstrates growth momentum via industry partnerships, a $53M Series B raise, and recognition like Fast Company's 2022 Innovation by Design finalist status across three categories.[1][7]
Founded in 2011 by Andras Forgacs and others with a mission to reimagine materials, sustainability, and consumption by replacing animal-derived and petrochemical-based inputs with nature-inspired alternatives.[3][5] The idea emerged from early tissue engineering efforts in a small lab to produce leather-like materials, evolving into a full biofabrication platform using DNA editing tools, yeast fermentation, and precision protein design.[4] Pivotal moments include expanding from leather alternatives to broader platforms like Bio-Alloy™ (a miscible plant-protein and bio-polymer blend) and Bio-F@rm™ for scalable protein production, with early traction through partnerships and tech transfers to manufacturing.[3][5][6] Leadership transitions, such as David Williamson as CTO and Catherine Roggero-Lovisi as CEO, have driven this shift toward commercial scalability.[4][7]
Modern Meadow stands out through proprietary, drop-in technologies that integrate seamlessly into existing infrastructure, enabling rapid adoption without high costs or retooling.[2][3][6]
Modern Meadow rides the synthetic biology and biofabrication wave, addressing climate-driven demands for circular materials amid leather industry shortages and petrochemical scrutiny.[2][3][8] Timing aligns with global sustainability regulations, rising consumer preference for ethical products, and synbio advancements in precision fermentation, enabling cost-competitive scaling.[4][5] Market forces like supply chain disruptions and ESG pressures favor its drop-in model, blurring lines between biotech, materials science, and consumer goods while fostering industry convergence.[1][3] It influences the ecosystem by setting benchmarks for protein-enabled dyeing (Bio-Shield™), reducing reliance on animal agriculture, and partnering to accelerate bio-based supply chains, catalyzing widespread adoption in fashion and beyond.[6][7][8]
Modern Meadow is poised to expand its protein platforms into high-volume applications like automotive and biomedical, leveraging partnerships for global scale and new formulations via ongoing R&D in AI and ecosystem connectivity.[1][5] Trends like regulatory pushes for PFAS bans, synbio cost reductions, and luxury brand sustainability mandates will propel growth, potentially amplifying its $53M-funded momentum toward market leadership.[1][7] Its influence may evolve from leather pioneer to materials powerhouse, redefining bio-alloys as standard for performance-driven sustainability—transforming biotech from niche to industry norm, much like its founding vision to build a greener world through scalable innovation.[2][3]
